Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been submitted. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.
View Top Employees from Zymeworks Inc.Website | http://www.zymeworks.com |
Ticker | ZYME |
Revenue | $29 million |
Funding | $819.8 million |
Employees | 328 (328 on RocketReach) |
Founded | 2003 |
Address | 540 - 1385 West 8th Ave, Vancouver, British Columbia V6H 3V9, CA |
Phone | (604) 678-1388 |
Fax | (604) 737-7077 |
Technologies |
JavaScript,
HTML,
Twitter
+75 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Business Services General, Antibody Therapeutics, Business Services, Science and Engineering, Bispecific Antibodies, Medical, Effector Function Modulation, Health Care, Serum Half-Life, Therapeutics |
Web Rank | 4 Million |
Keywords | Clinical-Stage Biopharmaceutical Company, Clinical Trials, Solid Tumors |
Competitors | Acceleron Pharma, Adagene, Affimed, Sutro Biopharma, Inc., Symphogen |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Zymeworks Inc. employee's phone or email?
The Zymeworks Inc. annual revenue was $29 million in 2024.
Kathy O'Driscoll is the Chief People Officer of Zymeworks Inc..
328 people are employed at Zymeworks Inc..
Zymeworks Inc. is based in Vancouver, British Columbia.
The NAICS codes for Zymeworks Inc. are [3254, 32541, 325, 32].
The SIC codes for Zymeworks Inc. are [28, 283].